HIPAA Alert: Potential Data Breach Learn More

Search
Close this search box.

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.

59 Clinical Trials
Lymphoma N/A Enrolling
nct/study# N/A / LYMPHOPROLIFERATIVE

Outcomes of Patients with Lymphoproliferative Disorders

Learn More
Lymphoma Phase II Enrolling
nct/study# NCT04728893 / MK-1026-003

A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies

Learn More
Lymphoma N/A Enrolling
nct/study# N/A / CORE-CLL-2018-0338

Chronic Lymphocytic Leukemia (CLL) Collaborative Study Of Real-World Evidence (CORE)

Learn More
Lymphoma Phase III Enrolling
nct/study# NCT06136559 / MK-1026-011

A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Ibrutinib as 1L+ Therapy in Participants with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)

Learn More
Lymphoma Phase III Enrolling
nct/study# NCT06561048 / CPI-818-004

A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physicians Choice Standard of Care Treatment (Selected Single Agent) in Participants with Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Learn More
Lymphoma N/A Enrolling
nct/study# N/A / MSK-20-100

Comparison of Clinical Trials Enrollment in Patient Records and Claims

Learn More

we are here for you

For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.